Knightscope Kicks Off Public Listing to Trade on NASDAQ
Knightscope, Inc., a developer of advanced physical security technologies focused on enhancing U.S. security operations, has commenced its offering of up to $40 million of Class A common stock, with shares to be listed immediately following closing on NASDAQ under the ticker symbol “KSCP."

NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $721.75
  • Forecasted Upside: 10.35 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$654.04
▲ +18.95 (2.98%)

This chart shows the closing price for REGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

Analyst Price Target is $721.75
▲ +10.35% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $721.75, with a high forecast of $850.00 and a low forecast of $565.00. The average price target represents a 10.35% upside from the last price of $654.04.

This chart shows the closing price for REGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Secure Silver Stock Play 2022
Here's one of the most secure silver stock plays in 2022.

Current Consensus is Buy

The current consensus among 18 polled investment analysts is to buy stock in Regeneron Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 18 buy ratings
  • 9 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 18 buy ratings
  • 9 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweightLow
12/6/2021The Goldman Sachs GroupInitiated CoverageBuy$824.00Medium
11/19/2021BMO Capital MarketsInitiated CoverageOutperform$780.00Low
11/10/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$700.00 ➝ $760.00Medium
11/5/2021SVB LeerinkBoost Price TargetOutperform$798.00 ➝ $850.00Medium
11/5/2021Morgan StanleyBoost Price TargetEqual Weight$571.00 ➝ $617.00Low
11/5/2021BenchmarkDowngradeBuy ➝ HoldHigh
11/5/2021HC WainwrightBoost Price TargetBuy$842.00 ➝ $844.00Medium
10/26/2021SVB LeerinkBoost Price TargetOutperform$785.00 ➝ $798.00Medium
10/22/2021HC WainwrightBoost Price TargetBuy$831.00 ➝ $842.00Low
10/12/2021Morgan StanleyLower Price TargetEqual Weight$606.00 ➝ $571.00Low
10/4/2021HC WainwrightReiterated RatingBuy$831.00High
9/21/2021BMO Capital MarketsBoost Price TargetOutperform$669.00 ➝ $706.00Low
9/15/2021Piper SandlerBoost Price TargetOverweight$675.00 ➝ $690.00Low
9/15/2021Cantor FitzgeraldBoost Price TargetOverweight$670.00 ➝ $700.00Medium
9/15/2021HC WainwrightBoost Price TargetBuy$787.00 ➝ $831.00Medium
9/9/2021UBS GroupInitiated CoverageBuy$763.00High
9/7/2021Morgan StanleyBoost Price TargetEqual Weight$576.00 ➝ $606.00Low
8/23/2021BenchmarkBoost Price TargetBuy$636.00 ➝ $727.00Low
8/20/2021HC WainwrightReiterated RatingBuy$787.00Low
8/6/2021BarclaysBoost Price TargetOverweight$675.00 ➝ $705.00Medium
8/6/2021SVB LeerinkBoost Price TargetOutperform$641.00 ➝ $725.00High
8/6/2021BMO Capital MarketsBoost Price TargetOutperform$625.00 ➝ $669.00High
8/6/2021OppenheimerBoost Price TargetOutperform$725.00 ➝ $825.00Medium
8/5/2021Piper SandlerBoost Price TargetOverweight$650.00 ➝ $675.00High
8/2/2021HC WainwrightBoost Price TargetBuy$729.00 ➝ $741.00Low
7/23/2021Royal Bank of CanadaBoost Price TargetSector Perform$629.00 ➝ $679.00Low
7/8/2021BenchmarkBoost Price TargetBuy$590.00 ➝ $636.00Low
6/29/2021HC WainwrightInitiated CoverageBuy$703.00Low
5/7/2021SVB LeerinkLower Price TargetOutperform$657.00 ➝ $641.00Low
5/7/2021Morgan StanleyBoost Price TargetEqual Weight$477.00 ➝ $495.00Low
4/19/2021Morgan StanleyLower Price TargetEqual Weight$525.00 ➝ $477.00Low
4/13/2021Robert W. BairdReiterated RatingHoldLow
4/13/2021Canaccord GenuityReiterated RatingBuyLow
3/26/2021SVB LeerinkBoost Price TargetOutperform$655.00 ➝ $657.00High
3/24/2021Canaccord GenuityReiterated RatingBuyHigh
2/24/2021Canaccord GenuityReiterated RatingBuyMedium
2/23/2021Credit Suisse GroupBoost Price TargetOutperform$753.00 ➝ $760.00High
2/16/2021Cantor FitzgeraldLower Price TargetOverweight$696.00 ➝ $656.00Low
2/8/2021Morgan StanleyLower Price TargetEqual Weight$553.00 ➝ $525.00Medium
2/8/2021Credit Suisse GroupLower Price TargetOutperform$758.00 ➝ $753.00Medium
2/8/2021CowenLower Price TargetOutperform$684.00 ➝ $565.00High
2/8/2021SVB LeerinkBoost Price TargetOutperform$623.00 ➝ $640.00High
1/25/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$630.00Medium
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$527.00 ➝ $553.00Low
1/14/2021Smith Barney CitigroupBoost Price Target$575.00 ➝ $584.00Low
1/13/2021BenchmarkUpgradeHold ➝ Buy$590.00Medium
1/8/2021FIXUpgradeNeutral ➝ Buy$635.00 ➝ $575.00Medium
12/16/2020Morgan StanleyLower Price TargetEqual Weight$602.00 ➝ $527.00Low
12/16/2020Credit Suisse GroupLower Price TargetOutperform$737.00 ➝ $736.00Medium
11/9/2020Morgan StanleyLower Price TargetEqual Weight$609.00 ➝ $602.00High
11/6/2020TruistBoost Price Target$750.00 ➝ $770.00Low
11/6/2020Credit Suisse GroupLower Price TargetOutperform$745.00 ➝ $737.00Low
11/6/2020SVB LeerinkBoost Price TargetOutperform$650.00 ➝ $653.00Low
11/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$626.00 ➝ $630.00Low
10/13/2020Morgan StanleyLower Price TargetEqual Weight$611.00 ➝ $609.00Low
10/6/2020SVB LeerinkBoost Price TargetOutperform$629.00 ➝ $650.00High
10/5/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$690.00High
10/1/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
8/20/2020BenchmarkDowngradeBuy ➝ HoldHigh
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$716.00 ➝ $725.00Low
8/6/2020BarclaysBoost Price Target$615.00 ➝ $675.00Low
8/6/2020Morgan StanleyLower Price TargetEqual Weight$619.00 ➝ $611.00Low
8/6/2020OppenheimerBoost Price TargetOutperform$675.00 ➝ $725.00Low
8/6/2020CitigroupBoost Price TargetNeutral$585.00 ➝ $635.00Low
8/6/2020BMO Capital MarketsBoost Price TargetOutperform$525.00 ➝ $626.00Low
8/5/2020The Goldman Sachs GroupBoost Price Target$700.00 ➝ $800.00Low
8/5/2020Piper SandlerBoost Price TargetOverweight$630.00 ➝ $675.00High
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$700.00 ➝ $716.00High
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$555.00 ➝ $619.00Low
7/8/2020SunTrust BanksUpgradeHold ➝ Buy$400.00 ➝ $750.00Low
7/8/2020Canaccord GenuityBoost Price TargetBuy$600.00 ➝ $700.00Low
7/1/2020OppenheimerBoost Price TargetOutperform$625.00 ➝ $675.00High
6/24/2020Credit Suisse GroupBoost Price TargetOutperform$605.00 ➝ $700.00High
6/12/2020Jefferies Financial GroupBoost Price TargetBuy$657.00 ➝ $691.00High
6/2/2020Jefferies Financial GroupReiterated RatingBuy$657.00Low
6/2/2020CowenReiterated RatingHold$584.00Low
6/2/2020OppenheimerReiterated RatingBuy$625.00Low
6/2/2020Cantor FitzgeraldBoost Price TargetNeutral$400.00 ➝ $624.00Low
5/28/2020BarclaysBoost Price Target$530.00 ➝ $615.00High
5/27/2020CfraLower Price TargetHold$557.00 ➝ $549.00Low
5/27/2020SVB LeerinkBoost Price TargetOutperform$622.00 ➝ $625.00High
5/26/2020SVB LeerinkReiterated RatingBuy$622.00Low
5/26/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$559.00 ➝ $734.00High
5/6/2020Robert W. BairdBoost Price TargetNeutral ➝ Neutral$487.00 ➝ $510.00High
5/6/2020Canaccord GenuityBoost Price TargetBuy$575.00 ➝ $630.00High
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$466.00 ➝ $525.00High
5/6/2020Royal Bank of CanadaLower Price Target$533.00 ➝ $524.00Medium
5/6/2020Piper SandlerBoost Price Target$550.00 ➝ $600.00Low
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$409.00 ➝ $555.00Medium
5/6/2020OppenheimerBoost Price TargetOutperform$525.00 ➝ $625.00High
5/6/2020Credit Suisse GroupBoost Price TargetOutperform$596.00 ➝ $605.00High
5/6/2020The Goldman Sachs GroupBoost Price TargetConviction-Buy$636.00 ➝ $700.00High
5/6/2020SVB LeerinkBoost Price TargetOutperform$604.00 ➝ $622.00High
5/1/2020Piper SandlerReiterated RatingOverweightLow
4/28/2020Canaccord GenuityBoost Price TargetBuy$550.00 ➝ $575.00Medium
4/28/2020CitigroupDowngradeBuy ➝ Neutral$540.00 ➝ $575.00High
4/19/2020BenchmarkInitiated CoverageHoldLow
4/17/2020BMO Capital MarketsBoost Price TargetMarket Perform$379.00 ➝ $466.00High
4/17/2020BenchmarkUpgradeHold ➝ Buy$655.00High
4/15/2020Morgan StanleyLower Price TargetEqual Weight$410.00 ➝ $409.00Medium
4/15/2020JPMorgan Chase & Co.Boost Price TargetNeutral$375.00 ➝ $429.00Medium
4/8/2020BenchmarkInitiated CoverageHoldMedium
4/7/2020SVB LeerinkBoost Price TargetOutperform$600.00 ➝ $604.00Medium
4/6/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$370.00 ➝ $435.00Low
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$455.00High
3/12/2020ArgusBoost Price TargetBuy$430.00 ➝ $540.00High
3/11/2020OppenheimerBoost Price TargetOutperform$450.00 ➝ $525.00Medium
3/4/2020CfraBoost Price TargetBuy ➝ Hold$460.00 ➝ $487.00High
3/4/2020Piper SandlerBoost Price Target$435.00 ➝ $500.00High
2/28/2020CowenBoost Price TargetMarket Perform$386.00 ➝ $495.00High
2/28/2020CitigroupBoost Price TargetBuy$420.00 ➝ $540.00High
2/27/2020BarclaysInitiated CoverageOverweight$530.00High
2/26/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00Medium
2/26/2020Credit Suisse GroupBoost Price TargetTop Pick ➝ Outperform$420.00 ➝ $510.00High
2/26/2020Robert W. BairdDowngradeOutperform ➝ Neutral$410.00High
2/26/2020Canaccord GenuityUpgradeHold ➝ Buy$409.00 ➝ $550.00High
2/25/2020Jefferies Financial GroupUpgradeHold ➝ Buy$355.00 ➝ $492.00High
2/24/2020Evercore ISIUpgradeIn-Line ➝ Outperform$500.00High
2/11/2020ArgusUpgradeHold ➝ Buy$430.00Medium
2/7/2020Evercore ISIInitiated CoverageHold$400.00Low
2/7/2020Morgan StanleyLower Price TargetEqual Weight$411.00 ➝ $410.00Low
2/7/2020SunTrust BanksBoost Price TargetHold$400.00High
1/22/2020OppenheimerBoost Price TargetOutperform$430.00 ➝ $450.00Low
1/17/2020Morgan StanleyBoost Price TargetEqual Weight$387.00 ➝ $411.00Low
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
12/23/2019Raymond JamesInitiated CoverageMarket PerformN/A
12/13/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
12/9/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
11/12/2019SunTrust BanksInitiated CoverageHold$360.00Medium
11/11/2019Evercore ISIReiterated RatingBuy$395.00Low
11/6/2019CitigroupUpgradeNeutral ➝ Buy$340.00 ➝ $420.00Low
11/6/2019OppenheimerLower Price Target$480.00 ➝ $430.00Low
11/6/2019BMO Capital MarketsBoost Price TargetMarket Perform$344.00 ➝ $358.00Medium
11/6/2019JPMorgan Chase & Co.Reiterated RatingHold$375.00Medium
11/6/2019Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$310.00 ➝ $340.00Medium
10/16/2019Bank of AmericaInitiated CoverageNeutral$325.00Low
10/9/2019Canaccord GenuityLower Price TargetHold$353.00 ➝ $320.00Medium
10/8/2019CowenSet Price TargetHold$349.00Low
10/8/2019Piper Jaffray CompaniesSet Price TargetBuy$435.00Low
10/8/2019BMO Capital MarketsSet Price TargetHold$344.00Low
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$355.00 ➝ $403.00Low
8/7/2019Robert W. BairdUpgradeNeutral ➝ Outperform$410.00Low
8/7/2019Credit Suisse GroupLower Price TargetNeutral$333.00 ➝ $325.00Low
8/7/2019BMO Capital MarketsLower Price TargetMarket Perform$344.00Low
7/29/2019CowenReiterated RatingHold$353.00Medium
6/21/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
6/18/2019ArgusDowngradeBuy ➝ HoldHigh
6/14/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
6/11/2019SVB LeerinkSet Price TargetBuy$453.00Low
5/23/2019CitigroupLower Price TargetNeutral ➝ Neutral$396.00 ➝ $340.00Low
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$336.00High
5/13/2019Cantor FitzgeraldLower Price TargetNeutral$441.00 ➝ $405.00Medium
5/8/2019BMO Capital MarketsLower Price TargetPositive ➝ Market Perform$412.00 ➝ $375.00Medium
5/8/2019Morgan StanleyLower Price TargetEqual Weight$420.00 ➝ $389.00Medium
5/8/2019Canaccord GenuityReiterated RatingHold ➝ Hold$408.00 ➝ $353.00High
5/8/2019UBS GroupLower Price TargetBuy$480.00 ➝ $440.00Medium
5/7/2019Piper Jaffray CompaniesReiterated RatingOverweight$435.00Medium
5/7/2019CowenReiterated RatingHold$353.00Medium
4/17/2019Jefferies Financial GroupLower Price TargetHold$376.00 ➝ $343.00High
2/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$487.00Medium
2/22/2019GuggenheimDowngradeBuy ➝ Neutral$466.00 ➝ $425.00Low
2/7/2019OppenheimerBoost Price TargetOutperform$440.00 ➝ $480.00Low
2/7/2019BMO Capital MarketsBoost Price TargetMarket Perform$412.00Low
2/6/2019Cantor FitzgeraldReiterated RatingHold$441.00High
1/7/2019CowenReiterated RatingHold$385.00Low
1/4/2019GuggenheimUpgradeNeutral ➝ Buy$461.00High
12/13/2018The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
12/7/2018SVB LeerinkSet Price TargetBuy$473.00 ➝ $483.00Low
12/2/2018OppenheimerSet Price TargetBuy$440.00High
11/13/2018ArgusReiterated RatingBuyLow
11/7/2018JPMorgan Chase & Co.Set Price TargetHold$405.00Medium
11/6/2018CowenReiterated RatingHold$385.00Medium
10/22/2018CowenReiterated RatingHold$385.00Medium
10/22/2018Cantor FitzgeraldBoost Price TargetNeutral$441.00Low
10/22/2018JPMorgan Chase & Co.Set Price TargetHold$405.00Low
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$409.00 ➝ $412.00High
10/11/2018Canaccord GenuityBoost Price TargetHold$390.00 ➝ $410.00High
10/2/2018JPMorgan Chase & Co.Reiterated RatingHoldMedium
10/1/2018SVB LeerinkBoost Price TargetOutperform$506.00 ➝ $512.00High
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$415.00High
8/16/2018CowenReiterated RatingHold$385.00Low
8/6/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$290.00 ➝ $305.00Low
8/3/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$304.00 ➝ $390.00Low
8/3/2018SunTrust BanksReiterated RatingHold$400.00Low
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$396.00 ➝ $409.00Low
8/3/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
8/2/2018BMO Capital MarketsSet Price TargetHold$388.00Low
7/24/2018Jefferies Financial GroupReiterated RatingHold$340.00Medium
7/19/2018Canaccord GenuityReiterated Rating$367.74$304.00Low
7/16/2018ArgusBoost Price TargetBuy ➝ Buy$383.00 ➝ $415.00Low
7/13/2018Morgan StanleyBoost Price TargetEqual Weight$370.00 ➝ $396.00Low
7/2/2018SunTrust BanksSet Price TargetHold$344.00Low
6/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$325.00High
6/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
5/23/2018BarclaysSet Price TargetSell$290.00Low
5/7/2018Royal Bank of CanadaLower Price TargetSector Perform$342.00Low
5/5/2018Credit Suisse GroupSet Price TargetBuy$420.00Low
5/4/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$400.00 ➝ $370.00Low
5/4/2018Canaccord GenuityLower Price TargetHold ➝ Hold$356.00 ➝ $304.00Low
5/4/2018SVB LeerinkSet Price TargetBuy$502.00 ➝ $435.00Low
5/4/2018BMO Capital MarketsSet Price TargetMarket Perform ➝ Hold$398.00 ➝ $361.00Low
5/4/2018CowenReiterated RatingOutperform$400.00 ➝ $350.00Low
5/4/2018SunTrust BanksLower Price TargetHold$344.00Low
5/3/2018BarclaysSet Price TargetSell$290.00Low
5/1/2018GuggenheimDowngradeBuy ➝ NeutralLow
4/27/2018Credit Suisse GroupSet Price TargetBuy$420.00High
4/27/2018CowenReiterated RatingHold$400.00Low
4/17/2018Credit Suisse GroupLower Price TargetBuy$440.00 ➝ $420.00Low
4/9/2018Raymond JamesReiterated RatingOutperform ➝ Market PerformLow
4/9/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
3/13/2018BTIG ResearchReiterated RatingHoldMedium
3/13/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$367.00Medium
2/21/2018Canaccord GenuityDowngradeBuy ➝ Hold$522.00 ➝ $356.00Medium
2/13/2018BTIG ResearchReiterated RatingHoldHigh
2/9/2018SunTrust BanksSet Price TargetHold$430.00Low
2/9/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$401.00 ➝ $415.00High
2/9/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$568.00 ➝ $502.00High
2/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
2/9/2018GuggenheimSet Price TargetBuy$530.00High
2/8/2018Jefferies Financial GroupReiterated RatingNeutral ➝ Hold$380.00High
2/8/2018BTIG ResearchDowngradeBuy ➝ Neutral$480.00High
2/8/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$398.00 ➝ $444.00Low
2/7/2018Credit Suisse GroupSet Price TargetBuy$440.00High
2/7/2018CowenReiterated RatingHold$450.00High
2/7/2018Canaccord GenuityReiterated RatingBuy$522.00High
2/2/2018Jefferies Financial GroupReiterated RatingHold$421.00Medium
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$455.00 ➝ $457.00Low
1/9/2018CitigroupReiterated RatingNeutral ➝ Neutral$380.00 ➝ $388.00High
12/28/2017ArgusLower Price TargetPositive ➝ Buy$540.00 ➝ $470.00Low
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00Low
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$397.00Medium
12/1/2017CitigroupDowngradeBuy ➝ Neutral$480.00 ➝ $380.00High
11/28/2017JPMorgan Chase & Co.Reiterated RatingHoldMedium
11/28/2017BTIG ResearchLower Price TargetBuy ➝ Buy$520.00 ➝ $480.00Low
11/27/2017BMO Capital MarketsSet Price TargetHold$444.00High
11/22/2017BTIG ResearchReiterated RatingBuy$520.00Low
11/16/2017Evercore ISILower Price TargetOutperform$605.00 ➝ $445.00N/A
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/A
11/9/2017Morgan StanleyLower Price TargetEqual Weight$490.00 ➝ $463.00N/A
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$473.00 ➝ $425.00N/A
11/9/2017BMO Capital MarketsLower Price TargetMarket Perform$491.00 ➝ $479.00N/A
11/9/2017CitigroupReiterated RatingBuy$480.00N/A
11/3/2017Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
10/31/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$540.00N/A
10/20/2017BarclaysDowngradeEqual Weight ➝ Underweight$450.00 ➝ $395.00N/A
10/16/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
10/16/2017Canaccord GenuityReiterated RatingBuyN/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$450.00 ➝ $490.00N/A
10/6/2017Jefferies Financial GroupReiterated RatingHold$471.00 ➝ $500.00N/A
10/2/2017SunTrust BanksReiterated RatingHold$435.00Medium
9/29/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$540.00High
9/27/2017OppenheimerReiterated RatingHoldLow
9/21/2017UBS GroupLower Price TargetBuy$535.00 ➝ $500.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$475.00Medium
9/11/2017Canaccord GenuityReiterated RatingBuy$522.00Low
9/11/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
9/8/2017Robert W. BairdReiterated RatingSell$408.00Low
9/7/2017CitigroupReiterated RatingBuy$575.00Low
9/6/2017Raymond JamesReiterated RatingOutperform ➝ Outperform$566.00Low
8/23/2017Morgan StanleyReiterated RatingEqual Weight$450.00Low
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$605.00Medium
8/15/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
8/15/2017SVB LeerinkReiterated RatingOutperform ➝ Positive$580.00 ➝ $552.00Low
8/14/2017Canaccord GenuitySet Price TargetBuy$522.00Low
8/9/2017Jefferies Financial GroupReiterated RatingHold$418.00 ➝ $471.00Low
8/9/2017The Goldman Sachs GroupReiterated RatingNeutral$469.00 ➝ $472.00Low
8/9/2017JPMorgan Chase & Co.Reiterated RatingHold$427.00 ➝ $455.00Low
8/9/2017SVB LeerinkReiterated RatingOutperform$573.00 ➝ $580.00Low
8/8/2017Robert W. BairdDowngradeNeutral ➝ Underperform$408.00Low
8/4/2017UBS GroupReiterated RatingBuy ➝ Buy$489.00 ➝ $535.00Low
8/4/2017CitigroupBoost Price TargetBuy$555.00 ➝ $575.00Low
8/3/2017BMO Capital MarketsSet Price TargetHold$491.00Low
8/3/2017Canaccord GenuitySet Price TargetBuy$522.00Low
8/3/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
8/1/2017Piper Jaffray CompaniesReiterated RatingOverweight$557.00High
8/1/2017Robert W. BairdDowngradeNeutral ➝ Underperform$408.00High
7/31/2017BMO Capital MarketsReiterated RatingMarket Perform$484.00High
7/28/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$484.00 ➝ $522.00Low
7/22/2017BarclaysReiterated RatingEqual Weight$400.00 ➝ $450.00Low
7/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00 ➝ $484.00Low
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 ➝ $593.00Low
7/14/2017Credit Suisse GroupDowngradeHold$485.00Low
7/10/2017Morgan StanleyReiterated RatingEqual Weight$405.00 ➝ $450.00Medium
6/30/2017BTIG ResearchReiterated RatingBuy ➝ Buy$480.00 ➝ $540.00High
6/28/2017SVB LeerinkReiterated RatingOutperform$493.00 ➝ $573.00Low
6/26/2017Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$410.00 ➝ $480.00Low
6/22/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$573.00Medium
6/22/2017Raymond JamesReiterated RatingOutperform$475.00 ➝ $547.00Medium
6/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00Low
6/20/2017Canaccord GenuitySet Price TargetBuy$484.00Low
6/20/2017Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$446.00 ➝ $557.00Low
6/14/2017OppenheimerReiterated RatingHoldLow
6/13/2017SVB LeerinkReiterated RatingOutperform$493.00Low
5/25/2017Sanford C. BernsteinReiterated RatingOutperformHigh
5/15/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
5/15/2017CowenReiterated RatingHold$380.00Low
5/15/2017BMO Capital MarketsBoost Price TargetHold$412.00 ➝ $421.00Low
5/8/2017BarclaysBoost Price TargetEqual Weight$375.00 ➝ $400.00Low
5/5/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
5/5/2017UBS GroupSet Price TargetBuy$446.00 ➝ $489.00N/A
5/5/2017Canaccord GenuityUpgradeHold ➝ Buy$375.00 ➝ $484.00Low
5/5/2017CowenReiterated RatingHold$380.00Low
5/5/2017BMO Capital MarketsReiterated RatingHold$412.00 ➝ $421.00Low
5/4/2017OppenheimerReiterated RatingHoldLow
4/12/2017Jefferies Financial GroupReiterated RatingHold$357.00Low
3/30/2017Canaccord GenuityReiterated RatingHold$375.00Low
3/29/2017BTIG ResearchReiterated RatingBuy$460.00Medium
3/29/2017UBS GroupBoost Price TargetBuy ➝ Buy$435.00 ➝ $446.00N/A
3/28/2017BMO Capital MarketsReiterated RatingHold$408.00 ➝ $412.00Low
3/28/2017SVB LeerinkSet Price TargetBuy$448.00Low
3/28/2017Robert W. BairdReiterated RatingNeutral$369.00Low
3/20/2017SVB LeerinkReiterated RatingOutperformHigh
3/20/2017BTIG ResearchReiterated RatingBuy$460.00Low
3/17/2017Canaccord GenuityReiterated RatingHold$375.00Low
3/17/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLow
3/16/2017OppenheimerInitiated CoverageHoldHigh
3/9/2017UBS GroupInitiated CoverageBuy ➝ Buy$435.00N/A
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$446.00Low
2/16/2017The Goldman Sachs GroupDowngradeBuy ➝ NeutralN/A
2/16/2017Sanford C. BernsteinReiterated RatingOutperform$420.00 ➝ $410.00N/A
2/13/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$359.87 ➝ $446.00N/A
2/11/2017SVB LeerinkSet Price TargetBuy$448.00N/A
2/10/2017Canaccord GenuityReiterated RatingHold$450.00N/A
2/10/2017Morgan StanleyLower Price TargetEqual Weight$370.00 ➝ $367.00N/A
2/10/2017CitigroupReiterated RatingBuy$420.00N/A
2/10/2017Sanford C. BernsteinLower Price Target$410.00N/A
2/10/2017Credit Suisse GroupReiterated RatingBuy$485.00N/A
2/9/2017CowenSet Price TargetHold$380.00N/A
2/6/2017The Goldman Sachs GroupLower Price TargetBuy$448.00 ➝ $446.00N/A
2/3/2017Canaccord GenuitySet Price TargetHold$450.00N/A
1/22/2017JPMorgan Chase & Co.Set Price TargetHold$440.00N/A
1/11/2017CowenReiterated RatingMarket Perform$400.00 ➝ $380.00N/A
1/10/2017SVB LeerinkReiterated RatingOutperformN/A
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformN/A
1/9/2017Morgan StanleySet Price TargetHold$420.00 ➝ $370.00N/A
1/8/2017Evercore ISISet Price TargetHold$421.00N/A
1/8/2017Robert W. BairdReiterated RatingNeutral$379.00 ➝ $369.00N/A
1/8/2017BTIG ResearchReiterated RatingBuy$460.00N/A
1/6/2017Royal Bank of CanadaReiterated RatingOutperform$626.00 ➝ $598.00N/A
1/6/2017Royal Bank of CanadaLower Price TargetOutperform$626.00 ➝ $598.00N/A
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 ➝ $345.00N/A
12/28/2016ArgusReiterated RatingBuy$450.00N/A
12/20/2016SVB LeerinkSet Price TargetBuy$492.00N/A
12/20/2016BMO Capital MarketsInitiated CoverageMarket Perform$419.00N/A
12/20/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$481.00 ➝ $485.00N/A
12/16/2016BTIG ResearchUpgradeNeutral ➝ Buy$460.00N/A
12/12/2016Canaccord GenuitySet Price TargetHold$450.00N/A
12/12/2016Robert W. BairdReiterated RatingPositive$379.00N/A
12/12/2016Chardan CapitalUpgradeSell ➝ Neutral$300.00 ➝ $350.00N/A
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/12/2021
  • 11 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/11/2021
  • 12 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/10/2021
  • 16 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
10/10/2021
  • 12 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
11/9/2021
  • 19 very positive mentions
  • 38 positive mentions
  • 12 negative mentions
  • 6 very negative mentions
12/9/2021

Current Sentiment

  • 19 very positive mentions
  • 38 positive mentions
  • 12 negative mentions
  • 6 very negative mentions

Recent Stories by Sentiment

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Read More

Today's Range

Now: $654.04
Low: $633.33
High: $655.75

50 Day Range

MA: $607.60
Low: $543.48
High: $654.40

52 Week Range

Now: $654.04
Low: $441.00
High: $686.62

Volume

672,772 shs

Average Volume

844,804 shs

Market Capitalization

$70.34 billion

P/E Ratio

10.44

Dividend Yield

N/A

Beta

0.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?

The following equities research analysts have issued stock ratings on Regeneron Pharmaceuticals in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Canaccord Genuity, Cantor Fitzgerald, Cowen Inc, Credit Suisse Group AG, FIX, HC Wainwright, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for REGN.

What is the current price target for Regeneron Pharmaceuticals?

16 Wall Street analysts have set twelve-month price targets for Regeneron Pharmaceuticals in the last year. Their average twelve-month price target is $721.75, suggesting a possible upside of 10.4%. SVB Leerink LLC has the highest price target set, predicting REGN will reach $850.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $565.00 for Regeneron Pharmaceuticals in the next year.
View the latest price targets for REGN.

What is the current consensus analyst rating for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals currently has 4 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REGN will outperform the market and that investors should add to their positions of Regeneron Pharmaceuticals.
View the latest ratings for REGN.

What other companies compete with Regeneron Pharmaceuticals?

How do I contact Regeneron Pharmaceuticals' investor relations team?

Regeneron Pharmaceuticals' physical mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company's listed phone number is (914) 847-7000 and its investor relations email address is [email protected] The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Knightscope Kicks Off Public Listing to Trade on NASDAQ
Knightscope, Inc., a developer of advanced physical security technologies focused on enhancing U.S. security operations, has commenced its offering of up to $40 million of Class A common stock, with shares to be listed immediately following closing on NASDAQ under the ticker symbol “KSCP."